Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
1999 3
2000 1
2002 2
2003 4
2004 5
2005 6
2006 8
2007 5
2008 3
2009 2
2010 2
2011 2
2012 9
2013 8
2014 6
2015 3
2016 4
2018 1
2019 2
2020 1
2021 3
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
ARGX-117, a therapeutic complement inhibiting antibody targeting C2.
Van de Walle I, Silence K, Budding K, Van de Ven L, Dijkxhoorn K, de Zeeuw E, Yildiz C, Gabriels S, Percier JM, Wildemann J, Meeldijk J, Simons PJ, Boon L, Cox L, Holgate R, Urbanus R, Otten HG, Leusen JHW, Blanchetot C, de Haard H, Hack CE, Boross P. Van de Walle I, et al. Among authors: boross p. J Allergy Clin Immunol. 2021 Apr;147(4):1420-1429.e7. doi: 10.1016/j.jaci.2020.08.028. Epub 2020 Sep 11. J Allergy Clin Immunol. 2021. PMID: 32926878 Free PMC article.
Editorial: Effector functions of therapeutic antibodies.
Boross P, Peipp M, Nimmerjahn F. Boross P, et al. Front Immunol. 2023 Jan 12;13:1126966. doi: 10.3389/fimmu.2022.1126966. eCollection 2022. Front Immunol. 2023. PMID: 36713416 Free PMC article. No abstract available.
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.
Kemper K, Gielen E, Boross P, Houtkamp M, Plantinga TS, de Poot SA, Burm SM, Janmaat ML, Koopman LA, van den Brink EN, Rademaker R, Verzijl D, Engelberts PJ, Satijn D, Sasser AK, Breij EC. Kemper K, et al. Among authors: boross p. Life Sci Alliance. 2022 Sep 8;5(11):e202201481. doi: 10.26508/lsa.202201481. Print 2022 Nov. Life Sci Alliance. 2022. PMID: 36271507 Free PMC article.
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity.
Hiemstra IH, Santegoets KCM, Janmaat ML, De Goeij BECG, Ten Hagen W, van Dooremalen S, Boross P, van den Brakel J, Bosgra S, Andringa G, van Kessel-Welmers B, Verzijl D, Hibbert RG, Frerichs KA, Mutis T, van de Donk NWCJ, Ahmadi T, Satijn D, Sasser AK, Breij ECW. Hiemstra IH, et al. Among authors: boross p. EBioMedicine. 2023 Jul;93:104663. doi: 10.1016/j.ebiom.2023.104663. Epub 2023 Jun 26. EBioMedicine. 2023. PMID: 37379657 Free PMC article.
Logic-gated antibody pairs that selectively act on cells co-expressing two antigens.
Oostindie SC, Rinaldi DA, Zom GG, Wester MJ, Paulet D, Al-Tamimi K, van der Meijden E, Scheick JR, Wilpshaar T, de Jong B, Hoff-van den Broek M, Grattan RM, Oosterhoff JJ, Vignau J, Verploegen S, Boross P, Beurskens FJ, Lidke DS, Schuurman J, de Jong RN. Oostindie SC, et al. Among authors: boross p. Nat Biotechnol. 2022 Oct;40(10):1509-1519. doi: 10.1038/s41587-022-01384-1. Epub 2022 Jul 25. Nat Biotechnol. 2022. PMID: 35879362 Free PMC article.
Boosting antibody therapy with complement.
Boross P, Leusen JH. Boross P, et al. Blood. 2012 Jun 21;119(25):5945-7. doi: 10.1182/blood-2012-04-420760. Blood. 2012. PMID: 22730521 Free article.
81 results